Dual Immunohistochemistry for PAS and CD31

PAS and CD31 detection in FFPE slides was conducted as previously described [54 (link),55 (link)]. The slides were first immunostained with CD31 (Abcam, Cambridge, UK, ab124432) as described above. After secondary antibody incubation, PAS staining was performed following the manufacturer’s recommendations (Sigma, St. Louis, MO, USA, 395B-1KT). Briefly, the slides were incubated for 5 min at room temperature with PAS, washed, and incubated for 15 min with Schiff’s Reagent. The slides were then counterstained with hematoxylin, dehydrated, and mounted.

Free full text: Click here

Recouvreux M.S., Miao J., Gozo M.C., Wu J., Walts A.E., Karlan B.Y, & Orsulic S. (2022). FOXC2 Promotes Vasculogenic Mimicry in Ovarian Cancer. Cancers, 14(19), 4851.

Publication 2022

ab124432 395B-1KT

Antibody Hematoxylin Schiff reagent

Corresponding Organization : VA Greater Los Angeles Healthcare System

Other organizations : Massachusetts General Hospital, Cedars-Sinai Medical Center

Top 5 similar protocols

Variable analysis

independent variables

Immunostaining with CD31 (Abcam, Cambridge, UK, ab124432)

dependent variables

PAS staining

control variables

Immunostaining protocol described in previous studies [54, 55]
Manufacturer's recommendations for PAS staining (Sigma, St. Louis, MO, USA, 395B-1KT)

controls

Positive controls not explicitly mentioned
Negative controls not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!